Antitubercular therapy in patients with cirrhosis: challenges and options - Test2 - elhamkhani - TriplyDB

Antitubercular therapy in patients with cirrhosis: challenges and options

Antitubercular therapy in patients with cirrhosis: challenges and options

http://www.wikidata.org/entity/Q33626827

about

A theoretical study on predicted protein targets of apple polyphenols and possible mechanisms of chemoprevention in colorectal cancer The effect of tuberculosis on the mortality of cirrhotic patients: a population-based 3-year follow-up study Is the Prophylactic Use of Hepatoprotectants Necessary in Anti-Tuberculosis Treatment?Liver Fatty Acid Binding Protein Deficiency Provokes Oxidative Stress, Inflammation, and Apoptosis-Mediated Hepatotoxicity Induced by Pyrazinamide in Zebrafish Larvae Antituberculosis Drug-Induced Liver Injury with Autoimmune Features: Facing Diagnostic and Treatment Challenges Anti-tuberculosis treatments and risk of hepatocellular carcinoma in tuberculosis patients with liver cirrhosis: a population-based case-control study.Comparative lipidomics of drug sensitive and resistant Mycobacterium tuberculosis reveals altered lipid imprints.

P2860

Q28831453-5CA712DE-611D-4260-9FB3-02943A44C77A Q36153859-9EB4F269-39AE-4D5C-8673-810AA9B3BFFD Q36368104-A68A709C-9B7B-40F9-9927-792BB7F8C42C Q37428683-D18E839D-3C54-4ED3-A678-831A83747B35 Q40367327-3724E68D-4F2D-498E-A80C-19DF37DB1462 Q43822028-3522CD49-A13D-4CBC-A6C0-1F1A5A3E8408 Q52684866-784570F7-A677-4849-8F79-AB81325D61F4

P2860

Antitubercular therapy in patients with cirrhosis: challenges and options

http://www.wikidata.org/entity/Q33626827

description

2014 nî lūn-bûn

@nan

2014 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Antitubercular therapy in patients with cirrhosis: challenges and options

@ast

Antitubercular therapy in patients with cirrhosis: challenges and options

@en

type

label

Antitubercular therapy in patients with cirrhosis: challenges and options

@ast

Antitubercular therapy in patients with cirrhosis: challenges and options

@en

prefLabel

Antitubercular therapy in patients with cirrhosis: challenges and options

@ast

Antitubercular therapy in patients with cirrhosis: challenges and options

@en

P1433

Q33626827-8C8245E5-E418-416F-9597-B81A5FCB49B1

P1476

Q33626827-DEC22694-ABDA-4E85-8B24-2872BB9952C0

P2093

Q33626827-08A98F55-36A2-4011-87BB-2124DC5FAF33

Q33626827-B13E094B-F37B-45A2-8C57-5CAAA137CE95

Q33626827-CB2007E6-D4A2-47C0-85A6-0C3888E45083

Q33626827-D5F3769B-6404-4BCB-BE87-9CAFD6345649

Q33626827-D9C550E9-0C55-4642-9303-B9C24EDEA706

P2860

Q33626827-036284A3-178B-4413-BCED-611DD896FAD3

Q33626827-0446F271-C5DE-49E8-88FF-FE5B89C37477

Q33626827-050A171D-11A3-40F2-8717-43B00020D355

Q33626827-06F5C28C-6CD0-4304-B572-C9205B6DC06D

Q33626827-07B9B98A-6DE8-47C0-907A-C9DEB9D8DEAA

Q33626827-0AAB087C-497E-464B-BA92-6CD765B3FDF9

Q33626827-0E61FD09-85A9-4B7B-8B6F-2A159330CD72

Q33626827-119A86C3-EF39-44F1-8BC8-06F22712BE91

Q33626827-14F90FA1-EC40-4556-B119-D8C5B7CE9A52

Q33626827-15C45F9B-44B3-41B7-A78E-AB0FF3EF791A

P304

Q33626827-0C07139B-BF99-49F8-8D21-BC9D0C26CA6B

P31

Q33626827-07D6EC8A-2E36-4F87-8FA6-4F28CA3886B1

P356

Q33626827-7B1BBCB3-54E5-4A8A-9208-DFF4E66A50DB

P407

Q33626827-5F027863-D346-47D6-B31F-4797385D31CB

P433

Q33626827-CE1BD7F8-8440-48AF-B55E-142FD710BFB2

P478

Q33626827-39254073-B636-428C-B188-89A0D4D3BFC2

P577

Q33626827-9BF91F38-B3ED-45F9-A76E-97AF0CCE8F47

P5875

Q33626827-CBA280B4-C0DB-46E7-B0C1-A00B5E64CAF0

P698

Q33626827-E6CA651B-BAA0-41E5-8463-4C9C1533E668

P932

Q33626827-391E0F29-B828-437E-A54C-AFA2AAE25EF1

P356

WJG.V20.I19.5760

P1433

World Journal of Gastroenterology

P1476

Antitubercular therapy in patients with cirrhosis: challenges and options

@en

P2093

Chandan Kumar Kedarisetty

http://www.w3.org/2001/XMLSchema#string

Naveen Kumar

http://www.w3.org/2001/XMLSchema#string

Sachin Kumar

http://www.w3.org/2001/XMLSchema#string

Shiv Kumar Sarin

http://www.w3.org/2001/XMLSchema#string

Vikas Khillan

http://www.w3.org/2001/XMLSchema#string

P2860

Ancient origin and gene mosaicism of the progenitor of Mycobacterium tuberculosis

The 19-kDa Mycobacterium tuberculosis protein induces macrophage apoptosis through Toll-like receptor-2

The embAB genes of Mycobacterium avium encode an arabinosyl transferase involved in cell wall arabinan biosynthesis that is the target for the antimycobacterial drug ethambutol

Structural mechanism for rifampicin inhibition of bacterial rna polymerase

Treatment of tuberculosis

Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis

Predisposing factors in hepatitis induced by isoniazid-rifampin treatment of tuberculosis

Isoniazid-related hepatitis: a U.S. Public Health Service cooperative surveillance study

Isoniazid-associated hepatitis in 114 patients

The human bile salt export pump: characterization of substrate specificity and identification of inhibitors

P304

5760-5772

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3748/WJG.V20.I19.5760

http://www.w3.org/2001/XMLSchema#string

P407

P433

19

http://www.w3.org/2001/XMLSchema#string

P478

20

http://www.w3.org/2001/XMLSchema#string

P577

2014-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

263016377

http://www.w3.org/2001/XMLSchema#string

P698

24914337

http://www.w3.org/2001/XMLSchema#string

P932

4024786

http://www.w3.org/2001/XMLSchema#string